Early clinical trial of new monoclonal antibody for treatment of CRPC
Posted Apr 26 2010 12:00am
TRACON Pharmaceuticals has announced the initiation of a Phase I/II clinical trial of its investigational monoclonal antibody TRC 105 for the treatment of patients with metastatic, castration-resistant prostate cancer (CRPC).
According to the company’s media release , issued earlier today, TRC 105 is a monoclonal antibody that binds to the CD105 receptor, and CD105 is an endothelial cell membrane receptor that is important to angiogenesis the process of leading to the formation of new blood vessels. TRACON and the trial investigators hope that by inhibiting angiogenesis and attacking blood vessels in established tumors, TRC105 may be able to demonstrate clinical activity against a wide variety of solid cancer types.
Earlier this year Roche announced that the combination of the angiogenesis inhibitor bevacizumab (Avastin) with docetaxel (Taxotere) did not appear to have significant impact on the survival of patients with metastatic CRPC. Avastin, like TRC 105, is a monoclonal antibody that affects angiogenesis. However, Avastin binds to vascular epithelial growth factor (VEGF) as opposed to CD105, so TRC 105 may have more appropriate effects on prostate cancer that Avastin.